Related Experiment Video

Updated: Jun 8, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population

J Klovaite1, M Benn, S Yazdanyar

  • 1Department of Clinical Biochemistry and the Copenhagen General Population Study, Herlev Hospital, Herlev, Denmark.

Journal of Thrombosis and Haemostasis : JTH
|October 15, 2010
PubMed
Abstract

Insights

Increased mean platelet volume (MPV), a measure of platelet size, is linked to a higher risk of myocardial infarction (MI). This association holds true even when accounting for other cardiovascular risk factors in the general population.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Epidemiology

Background:

  • Platelet size, quantified by mean platelet volume (MPV), is an indicator of platelet activation.
  • Active platelets are larger and play a role in the development of myocardial infarction (MI).

Purpose of the Study:

  • To investigate the association between increased MPV and the risk of MI in the general population.
  • To determine if this association is independent of established cardiovascular risk factors.

Main Methods:

  • Analysis of data from 39,531 individuals in the Copenhagen General Population Study.
  • Prospective follow-up to identify 1300 cases of MI.

Main Results:

  • Higher MPV levels were significantly associated with an increased risk of MI after adjusting for cardiovascular risk factors.
  • Risk of MI increased progressively across tertiles, quintiles, and octiles of MPV.
  • MPV remained a significant predictor of MI risk, with a 38% increase in risk for MPV ≥ 7.4 fL.

Conclusions:

  • Elevated MPV is an independent risk factor for myocardial infarction.
  • MPV measurement can contribute to cardiovascular risk assessment.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...